We help international patients identify clinically available pathways, obtain hospital review and coordinate care in China — without confusing research activity, marketing claims and real clinical access.
Patients rarely begin with a city or hospital. They begin with a diagnosis, a therapy they have heard about, or an offer they are not sure they can trust.
01Explore whether a relevant regenerative medicine pathway may exist.
Explore conditions →
02Understand its clinical status, eligibility and realistic access route.
View pathways →
03Request an independent review of the provider, status and claims.
Verify an offer →
04Explore evidence-led longevity assessment, separate from treatment claims.
Healthy aging →These pathways have credible public information, but RMC will not label them as internationally available until the treating institution confirms current foreign-patient intake, criteria and pricing.
For COPD, interstitial lung disease, idiopathic pulmonary fibrosis and bronchiectasis cases requiring formal medical review.
View pathway →
A publicly reported cell-based clinical application pathway. MRI, clinical grading and treatment history are required.
View pathway →
A publicly reported regenerative clinical application pathway. Eligibility depends on metabolic function, complications and medical history.
View pathway →
RMC prepares the case and coordinates communication. The treating hospital decides whether further consultation, testing or treatment is appropriate.
Research activity, domestic clinical access and foreign-patient access are not the same. RMC separates them before a patient makes a travel decision.
RMC handles administrative preparation and communication. Only the treating hospital and physician can determine eligibility, treatment planning and medical fees.
From the first hospital review to arrival, admission and follow-up, RMC coordinates the non-medical steps that often make cross-border care difficult.
RMC can coordinate physician-led longevity and aging assessment. We do not market unverified “one-shot anti-aging” injections as proven treatment.
RMC uses research and technical information to understand a pathway, but only promotes clinical access after the regulatory route, responsible institution and current patient intake are verified.
These limits protect patients and help keep commercial claims separate from medical evidence.
Regenerative medicine does not guarantee improvement or cure.
Research participation is not sold as a paid treatment package.
Laboratory or early-stage research is not presented as available care.
Formal medical pricing should follow hospital assessment and planning.
Share your diagnosis, current treatment and key recent tests. We will first determine whether a potentially relevant pathway exists and what records a hospital would need.
Submit Your Case →